Extended-Wear Insulin Pumps

MiniMed Fit Offers Seven Days of Tubeless Insulin Delivery

Extended-wear insulin pumps are offering greater convenience for diabetes management, with MiniMed introducing its FDA-cleared MiniMed Fit system. The tubeless device combines automated insulin delivery with a seven-day wear period, allowing users to manage their condition with fewer equipment changes. Its waterproof design and smartphone controls also support greater flexibility throughout daily activities.

The system holds 300 units of insulin, providing 50% more capacity than other tubeless options. Its SmartGuard technology automatically adjusts insulin delivery and can administer correction doses every five minutes. Additional features include meal detection capabilities and compatibility with multiple glucose sensors.

For MiniMed, the device creates opportunities to expand into the tubeless insulin pump market while attracting consumers seeking less demanding diabetes management. Planned pharmacy distribution and increased manufacturing capacity could improve product accessibility and support commercial growth following its anticipated U.S. rollout in spring 2027.

Image Credit: MiniMed Fit

Extended-wear Diabetes Devices
Longer wear periods reduce maintenance burdens for patients and create space for higher-capacity, low-intervention chronic care technologies.
Tubeless Insulin Automation
Automated, patch-style insulin delivery reflects a shift toward discreet medical devices that blend continuous therapy with everyday mobility.
Smartphone-controlled Care
Mobile-enabled device management strengthens the role of consumer-friendly interfaces in complex treatment routines and connected health ecosystems.

Industries Being Reshaped

Diabetes Care
Advanced insulin delivery systems are reshaping competitive dynamics by prioritizing convenience, personalization, and reduced therapy friction.
Medical Devices
Waterproof, sensor-compatible wearables highlight opportunities for durable health hardware that supports uninterrupted use across daily environments.
Digital Health
Integrated algorithms, app controls, and glucose sensor compatibility point to expanding platforms for automated treatment decision support.
SCORE
8.2 out of 10
GENDER
50% Men50% Women
MARKETTop markets: North America
GENERATION
  • Gen Alpha
  • Gen X
  • Gen Z (primary audience)
  • Millennial (primary audience)
POPULARITY
Popularity 67%
Activity 78%
Freshness 100%